Viatris (VTRS) Total Non-Current Liabilities (2019 - 2026)
Viatris (VTRS) recorded quarterly Total Non-Current Liabilities of $20.1 billion in Q1 2026, down 1.82% quarter-over-quarter from $20.5 billion in Q4 2025, and down 4.22% on a YoY basis from $21.0 billion in Q1 2025.
Viatris (VTRS) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Viatris' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $20.1 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 4.22% year-over-year to $20.1 billion; the TTM figure through Mar 2026 stood at $20.1 billion (down 4.22% YoY), while the FY2025 annual figure was $20.5 billion, down 2.19% from the prior year.
- Total Non-Current Liabilities was $20.1 billion for Q1 2026 at Viatris, down from $20.5 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $31.1 billion in Q1 2022 to a low of $20.1 billion in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $24.7 billion across 5 years, with a median of $25.7 billion in 2023.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities advanced 1.28% in 2024, then dropped 22.25% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $27.2 billion in 2022, then declined by 5.49% to $25.7 billion in 2023, then fell by 18.58% to $20.9 billion in 2024, then retreated by 2.19% to $20.5 billion in 2025, then retreated by 1.82% to $20.1 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $20.1 billion (Q1 2026), $20.5 billion (Q4 2025), and $20.9 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Viatris | - | - | 1.16 Bn | 20.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.09 Bn |
| Dec 31, 2025 | 20.47 Bn |
| Sep 30, 2025 | 20.88 Bn |
| Jun 30, 2025 | 21.01 Bn |
| Mar 31, 2025 | 20.98 Bn |
| Dec 31, 2024 | 20.93 Bn |
| Sep 30, 2024 | 23.09 Bn |
| Jun 30, 2024 | 25.47 Bn |
| Mar 31, 2024 | 26.98 Bn |
| Dec 31, 2023 | 25.70 Bn |
| Sep 30, 2023 | 26.23 Bn |
| Jun 30, 2023 | 26.18 Bn |
| Mar 31, 2023 | 26.64 Bn |
| Dec 31, 2022 | 27.19 Bn |
| Sep 30, 2022 | 27.74 Bn |
| Jun 30, 2022 | 29.51 Bn |
| Mar 31, 2022 | 31.13 Bn |
| Sep 30, 2021 | 32.88 Bn |
| Jun 30, 2021 | 34.54 Bn |
| Mar 31, 2021 | 35.09 Bn |